Optimizing treatment of chronic myeloid leukemia: a rational approach.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  The Oncologist

• Publication date

  2004-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/THEONCOLOGIST.9-3-259PMID 15169981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hydroxyurea-induced acute alveolitis in a Patient with chronic myeloid leukaemia

  2004cited by this paper
• High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.

  2004cited by this paper
• Practical management of patients with chronic myeloid leukemia receiving imatinib.

  2003influential reference
• Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.

  2003cited by this paper
• Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.

  2003cited by this paper
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  2003cited by this paper
• Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

  2003cited by this paper
• Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.

  2003influential reference
• Interferon-alfa for chronic myeloid leukemia.

  2003cited by this paper
• Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.

  2003cited by this paper
• Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib

  2003influential reference
• Result of high-dose imatinib mesylate in patients with Philadelphia chromosome – positive chronic myeloid leukemia after failure of interferon -

  2003cited by this paper
• Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.

  2003cited by this paper
• Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis

  2003influential reference
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003influential reference
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003influential reference
• Stem cell transplantation for chronic myeloid leukemia in children.

  2003cited by this paper
• Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy

  2002cited by this paper
• Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

  2002cited by this paper
• Successful treatment for leg ulcers due to hydroxyurea in a patient with chronic myelogenous leukaemia.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.

  2002influential reference
• High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

  2002cited by this paper
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

  2002influential reference
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  2002cited by this paper
• BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

  2002cited by this paper
• Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results

  2002cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Muco‐cutaneous changes during long‐term therapy with hydroxyurea in chronic myeloid leukaemia

  2001cited by this paper
• The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Multicenter prospective study of interferon-α versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: a preliminary analysis

  2001cited by this paper
• Homoharringtonine

  2001cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000influential reference
• Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.

  2000cited by this paper
• A case of bilateral heel ulcers associated with hydroxyurea therapy for chronic myelogenous leukemia.

  2000cited by this paper
• Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

  2000cited by this paper
• Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

  2000cited by this paper
• Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry.

  2000cited by this paper
• Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

  2000cited by this paper
• Hydroxyurea-induced hypersensitivity pneumonitis: A case report and literature review.

  2000cited by this paper
• Role of 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI 571

  2000cited by this paper
• Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.

  2000cited by this paper
• Leg ulcer in hydroxyurea-treated patients.

  2000cited by this paper
• Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

  2000cited by this paper
• Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.

  2000cited by this paper
• Vasculitis and Leukemia

  2000cited by this paper
• An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

  1999cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• The biology of chronic myeloid leukemia.

  1999influential reference
• Hydroxyurea‐Related Leg Ulcers in a Patient with Chronic Myelogenous Leukemia: A Case Report and Review of the Literature

  1999cited by this paper
• Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia.

  1999cited by this paper
• Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.

  1998influential reference
• Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.

  1998influential reference
• Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group.

  1998cited by this paper
• Leg ulcers associated with long-term hydroxyurea therapy.

  1998cited by this paper
• Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation

  1998cited by this paper
• Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

  1998cited by this paper
• Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea.

  1998cited by this paper
• Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia.

  1998cited by this paper
• Long term follow up of the italian trial of Interferon-A versus conventional chemotherapy in Chronic Myeloid Leukemia

  1998cited by this paper
• Hydroxyurea-related ankle ulcers in patients with myeloproliferative disorders: a case report and review of the literature.

  1997cited by this paper
• Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea.

  1997cited by this paper
• Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.

  1997cited by this paper
• Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

  1997cited by this paper
• Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

  1997cited by this paper
• Marrow transplantation for CML: the Seattle experience.

  1996cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry.

  1996cited by this paper
• Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT).

  1996cited by this paper
• Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

  1995cited by this paper
• Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy

  1995cited by this paper
• UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.

  1995cited by this paper
• A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.

  1995cited by this paper
• Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.

  1995cited by this paper
• Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.

  1994cited by this paper
• Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.

  1994cited by this paper
• Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

  1994cited by this paper
• Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

  1993cited by this paper
• Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

  1993cited by this paper
• Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.

  1993cited by this paper
• Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation.

  1991cited by this paper
• Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.

  1991cited by this paper
• Acute leukaemia in bcr/abl transgenic mice

  1990cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

  1990cited by this paper
• Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

  1986cited by this paper
• Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage.

  1977cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• A minute chromosome in human chronic granulocytic leukemia

  1960cited by this paper
• Role of (cid:1) 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI571

  year unknowncited by this paper

• Leucémie myéloïde chronique : vingt ans d’analyses ciblées sur l’imatinib

  2023cites this paper
• Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study

  2020cites this paper
• Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia

  2020cites this paper
• Wasabi Compound 6-(Methylsulfinyl) Hexyl Isothiocyanate Induces Cell Death with Coexisting Mitotic Arrest and Autophagy in Human Chronic Myelogenous Leukemia K562 Cells

  2019cites this paper
• Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian’s with chronic myeloid leukemia

  2019cites this paper
• Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia

  2019cites this paper
• Factors Related to Poor Adherence to Oral Tyrosine Kinase Inhibitor Treatments in Chronic Myeloid Leukemia Patients in Finland

  2016influential citation
• Overexpression of CCAAT Enhancer-Binding Protein α Inhibits the Growth of K562 Cells via the Foxo3a-Bim Pathway

  2016cites this paper
• Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study.

  2016cites this paper
• Chronic Myeloid Leukemia Patients' Adherence to Tyrosine Kinase Inhibitors in Finland: A Journey of Eighty-six Patients

  2016cites this paper
• Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study

  2014cites this paper
• Observance des médicaments anticancéreux

  2013cites this paper
• [Anticancer drug adherence].

  2013cites this paper
• Air Space and Bronchi – I

  2013cites this paper
• Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients

  2012cites this paper
• Original article Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

  2012cites this paper
• Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

  2012cites this paper
• Long-term Treatment of Chronic Myeloid Leukemia

  2011cites this paper
• Predictive biomarkers: a paradigm shift towards personalized cancer medicine

  2011cites this paper
• The isolation and characterisation of MHC-presented peptides from CML-derived cell-lines, with a focus on post-translational modification

  2011influential citation
• Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia.

  2011cites this paper
• Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

  2011cites this paper
• Leukemianet Recommendations from an expert panel on behalf of the European Evolving concepts in the management of chronic myeloid leukemia.

  2011cites this paper
• Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.

  2010cites this paper
• Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance

  2010cites this paper
• Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

  2009cites this paper
• Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells.

  2009cites this paper
• NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

  2009cites this paper
• Chronic Myelogenous LeukemiaPractice Guidelines in Oncology TM

  2009cites this paper
• Allogeneic Stem Cell Transplantation for Pediatric and Adolescent Patients with CML: Results from the Prospective Trial CML-paed I

  2009cites this paper
• Chronic myelogenous leukemia.

  2009cites this paper
• Clinical Trials and Observations

  2008cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 70 Blood-Brain Barrier Transport Investigation of Active Efflux using Positron Emission Tomography and Modelling Studies

  2008cites this paper
• Dehydroalanine Analog of Glutathione: An Electrophilic Busulfan Metabolite That Binds to Human Glutathione S-Transferase A1-1

  2008cites this paper
• Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®) versus interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia

  2007cites this paper
• Chronic Myeloid Leukaemia in The 21st Century

  2007cites this paper
• Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.

  2007cites this paper
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2006cites this paper
• A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis

  2006cites this paper
• Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

  2006cites this paper
• Clinical trials design and treatment tailoring: general principles applied to breast cancer research.

  2006cites this paper
• Clinical Trials in the Era of Treatment Tailoring

  2006cites this paper
• Pharmacogenetics and Drug Development

  2005cites this paper
• How long will chronic myeloid leukemia patients treated with imatinib mesylate live?

  2005cites this paper
• Safety and efficacy of an indigenous recombinant interferon-alpha-2b in patients with chronic myelogenous leukaemia: results of a multicentre trial from India.

  2005cites this paper
• Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia

  2005influential citation
• Leucemia mieloide crónica: Actualización en Citogenética y Biología Molecular

  2005cites this paper
• A Simulation Study Using Validated Prognostic Factors to Assess Expected Long-term Survival

  2005cites this paper
• Indications for imatinib mesylate therapy and clinical management.

  2004cites this paper